Pharmacotherapeutic Options for Overweight Adolescents

Abstract

Spanish

French

Objective:

To evaluate the safety and efficacy of current pharmacotherapeutic options for weight loss in overweight adolescents.

Data Sources:

Literature was obtained through MEDLINE Ovid (1996–April 2007) and EMBASE Drugs and Pharmacology (1991–2nd quarter 2007) searches and a bibliographic review of published articles. Key words included adolescents, overweight, obesity, anti-obesity agents, drug therapy, orlistat, sibutramine, and metformin.

Study Selection and Data Extraction:

All studies published in the English language that evaluated the use of pharmacotherapy for the treatment of overweight adolescents were critically analyzed; pertinent articles were selected for this review.

Data Synthesis:

Orlistat has been approved for use in adolescents between the ages of 12 and 16 years. The most frequently reported adverse effects of orlistat were gastrointestinal; reduced concentrations of fat-soluble vitamins were also observed. Of the 6 clinical trials published, 5 have shown statistically significant reductions in body mass index {BMI) from baseline, ranging from 0.55 to 4.09 kg/m²; one small trial failed to demonstrate significant weight reduction compared with placebo. Sibutramine has also been evaluated for use in overweight adolescents in 6 trials. Trials demonstrated a statistically significant reduction in BMI up to 5.6 kg/m² (from baseline). Of concern is evidence indicating that sibutramine therapy may be associated with elevated blood pressure, increased pulse rate, depression, and suicidal ideations. Lastly, metformin has recently been evaluated for weight loss in overweight adolescents; small, short-term trials demonstrate modest reductions in weight and BMI.

Conclusions:

Orlistat has been proven both safe and effective for weight reduction in overweight adolescents. Sibutramine has also been proven effective in reducing weight in this population; however, the potential for severe adverse effects requires further investigation. Metformin has demonstrated promising results in small trials; its role in the treatment of overweight adolescents will remain investigational until further research is conducted.

Keywords

adolescents metformin obesity orlistat sibutramine

Get full access to this article

View all access options for this article.

References

Ogden

Flegal

Carroll

Johnson

. Prevalence and trends in overweight among US children and adolescents, 1999–2000. JAMA 2002;288:1728–32.

Ogden

Carroll

Flegal

. Epidemiologic trends in overweight and obesity. Endocrinol Metab Clin North Am 2003;32:741–60, vii.

National Institutes of Health, National Heart, Lung and Blood Institute, North American Association for the Study of Obesity. The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. NIH Publication 00-4084, October 2000 (online). www.nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf (accessed 2007 Apr 28).

BMI—body mass index: about BMI for children and teens. CDC. www.cdc.gov/nccdphp/dnpa/bmi/childrens_BMI/about_childrens_BMI.htm (accessed 2007 Apr 28).

Ogden

Carroll

Curtin

McDowell

Tabak

Flegal

. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 2006;295:1549–55. DOI 10.1001/jama.295.13.1549

Whitaker

Wright

Pepe

Seidel

Dietz

. Predicting obesity in young adulthood from childhood and parental obesity. N Engl J Med 1997;337:869–73.

Goran

Ball

Cruz

. Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents. J Clin Endocrinol Metab 2003;88:1417–27.

The Surgeon General's call to action to prevent and decrease overweight and obesity. www.surgeongeneral.gov/topics/obesity/calltoaction/fact_adolescents.htm (accessed 2007 Apr 28).

Freedman

Dietz

Srinivasan

Berenson

. The relation of overweight to cardiovascular risk factors among children and adolescents: the Bogalusa Heart Study. Pediatrics 1999;103:1175–82.

10.

Dietz

. Health consequences of obesity in youth: childhood predictors of adult disease. Pediatrics 1998;101:518–25.

11.

Must

Strauss

. Risks and consequences of childhood and adolescent obesity. Int J Obes Relat Metab Disord 1999;23(suppl 2):S2–11.

12.

Weiss

Dziura

Burgert

. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004;350:2362–74. DOI 10.1056/NEJMoa031049

13.

Cook

Weitzman

Auinger

Nguyen

Dietz

. Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988–1994. Arch Pediatr Adolesc Med 2003;157:821–37. DOI 10.1001/archpedi.157.8.821

14.

Fowler-Brown

Kahwati

. Prevention and treatment of overweight in children and adolescents. Am Fam Physician 2004;69:2591–8.

15.

Bays

. Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004;12:1197–211.

16.

Yanovski

. Intensive therapies for pediatric obesity. Pediatr Clin North Am 2001;48:1041–53.

17.

Fontbonne

Charles

Juhan-Vague

. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO study group. Diabetes Care 1996;19:920–6.

18.

Charles

Eschwege

Grandmottet

. Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab Res Rev 2000;16:2–7. DOI 10.1002/(SICI) 1520-7560(200001/02)

19.

Astrup

Caterson

Zelissen

. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004;12:1658–69.

20.

Wilding

Van Gaal

Rissanen

Vercruysse

Fitchet

, OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 2004;28:1399–410. DOI 10.1038/sj.ijo.0802783

21.

Anderson

Greenway

Fujioka

Gadde

McKenney

O'neil

. Bupropion SR enhances weight loss: a 48-week double-blind, placebo-controlled trial. Obes Res 2002;10:633–41.

22.

Gadde

Parker

Maner

. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res 2001;9:544–51.

23.

Jain

Kaplan

Gadde

. Bupropion SR vs placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002;10:1049–56.

24.

Keating

. Exenatide. Drugs 2005;65:1681–92.

25.

DeFronzo

Ratner

Han

Kim

Fineman

Baron

. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092–100.

26.

Kendall

Riddle

Rosenstock

. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083–91.

27.

Gadde

Franciscy

Wagner

2nd

Krishnan

. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003;289:1820–5.

28.

Freemark

Bursey

. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001;107: E55. http://pediatrics.aappublications.org/cgi/reprint/107/4/e55) (accessed 2007 Jan 3).

29.

Kay

Alemzadeh

Langley

D'angelo

Smith

Holshouser

. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001;50:1457–61. DOI 10.1053/meta.2001.28078

30.

Srinivasan

Ambler

Baur

. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab 2006;91:2074–80. DOI 10.1210/jc.2006-0241

31.

Liang

Zou

. Prevalence of the metabolic syndrome in Zhejiang Chinese obese children and adolescents and the effect of metformin combined with lifestyle intervention. Int J Obes 2007;31:15–22. DOI 10.1038/sj.ijo0803453

32.

Aarsen

van den Akker

Drop

Catsman-Berrevoets

. Effect of topiramate on cognition in obese children (letter). Neurology 2006;67:1307–8.

33.

Van Gaal

Rissanen

Scheen

Ziegler

Rossner

RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389–97. DOI 10.1016/S0140-6736(05)66374-X

34.

Pi-Sunyer

Aronne

Heshmati

Devin

Rosenstock

RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761–75. DOI 10.1001/jama.295.7.761

35.

Padwal

Lau

. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003;27:1437–46. DOI 10.1038/sj jjo.0802475

36.

Product information. Meridia (sibutramine hydrochloride monohydrate) capsules. North Chicago, IL: Abbott Laboratory, August 2006.

37.

Product information. Xenical (orlistat) capsules. Nutley, NJ: Roche Laboratories, January 2005.

38.

Zhi

Melia

Eggers

Joly

Patel

. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995;35:1103–8.

39.

Zhi

Mulligan

Hauptman

. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 1999;39:41–6.

40.

Halford

. Pharmacotherapy for obesity. Appetite 2006;46:6–10. DOI 10.1016/j.appet.2005.07.010

41.

Rossner

Sjostrom

Noack

Meinders

Noseda

. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European orlistat obesity study group. Obes Res 2000;8:49–61.

42.

Sjostrom

Rissanen

Andersen

. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European multicentre orlistat study group. Lancet 1998;352:167–72.

43.

Davidson

Hauptman

DiGirolamo

. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999;281:235–42.

44.

Finer

James

Kopelman

Lean

Williams

. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000;24:306–13.

45.

Hauptman

Lucas

Boldrin

Collins

Segal

. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000;9:160–7.

46.

Torgerson

Hauptman

Boldrin

Sjostrom

. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004;27:155–61.

47.

FDA CDER Division of Metabolic and Endocrine Drug Products (HFD-510). Clinical review for NDA 20-766/S018. www.fda.gov/cder/foi/esum/2003/20766se5-018_Orlistat_BPCA_CLINICAL_ltr.pdf (accessed 2007 Jan 8).

48.

FDA approves orlistat for over-the-counter use. www.fda.gov/bbs/topics/NEWS/2007/NEW01557.html (accessed 2007 Apr 28).

49.

McDuffie

Calis

Uwaifo

. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002;10:642–50.

50.

McDuffie

Calis

Uwaifo

. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab 2004;17:307–19.

51.

Norgren

Danielsson

Jurold

Lotborn

Marcus

. Orlistat treatment in obese prepubertal children: a pilot study. Acta Paediatr 2003;92:666–70.

52.

Ozkan

Bereket

Turan

Keskin

. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr 2004;163:738–41.

53.

Maahs

de Serna

Kolotkin

. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract 2006;12:18–28.

54.

Chanoine

Hampl

Jensen

Boldrin

Hauptman

. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005;293:2873–83. DOI 10.1001/jama.293.23.2873

55.

Zhi

Moore

Kanitra

. The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents. J Am Coll Nutr 2003;22:357–62.

56.

McDuffie

Calis

Booth

Uwaifo

Yanovski

. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002;22:814–22.

57.

Smith

Goulder

, On behalf of the Members of the Sibutramine Clinical Study 1047 Team. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract 2001; 50: 505–12.

58.

Porter

Raebel

Conner

. The long-term outcomes of sibutramine effectiveness on weight (LOSE weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. Am J Manag Care 2004;10:369–76.

59.

Wadden

Berkowitz

Womble

. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med 2005;353:2111–20. DOI 10.1056/NEJMoa050156

60.

Wirth

Krause

. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 2001;286:1331–9.

61.

James

Astrup

Finer

. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM study group. Sibutramine trial of obesity reduction and maintenance. Lancet 2000;356:2119–25.

62.

Berkowitz

Wadden

Tershakovec

Cronquist

. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 2003;289:1805–12. DOI 10.1001/jama.289.14.1805

63.

Godoy-Matos

Carraro

Vieira

. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab 2005;90:1460–5. DOI 10.1210/jc.2004-0263

64.

Violante-Ortiz

Del-Rio-Navarro

Lara-Esqueda

. Use of sibutramine in obese Hispanic adolescents. Adv Ther 2005;22:642–9.

65.

Berkowitz

Fujioka

Daniels

. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med 2006;145:81–90.

66.

Garcia-Morales

Berber

Macias-Lara

Lucio-Ortiz

Del-Rio-Navarro

Dorantes-Alvarez

. Use of sibutramine in obese Mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2006;28:770–82. DOI 10.1016/j.clinther.2006.05.008

67.

Reisler

Tauber

Afriat

Bortnik

Goldman

. Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity. Isr Med Assoc J 2006;8:30–2.

68.

Beaston

. Clinical review for NDA 20-632,SE5-021. www.fda.gov/cder/foi/esum/2005/020632s021_sibutramine_hydrochloride_clinical_BPCA.pdf (accessed 2007 Apr 28).

69.

Barlow

Dietz

. Obesity evaluation and treatment: expert committee recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Services. Pediatrics 1998;102: E29. http://pediatrics.aappublications.org/cgi/reprint/102/3/e29 (accessed 2007 Apr 28).